Figure 4.
Increasing soluble VWF concentration enhances SIPA rate and shortens time to occlusion. Agglomeration (A) and superficial velocity (C) over time for VWF concentrations ranging from 0.1 times to 18 times normal. Higher VWF concentrations cause faster agglomeration and decrease the traveling velocity. The corresponding agglomeration rate (B) and capture time (D) calculated based on (A) and (C), respectively. (E) Increasing the concentration of soluble VWF by 20-fold leads to 50% reduction of the OT. The API was inverted as 400-API. (F) The predicted enhancement of SIPA rates (in terms of agglomeration rate and 1/capture time) are elevated for high sVWF concentration that leads to an enhanced rate for arterial occlusion plotted as 1/OT from experiments. (***P < .0001). For each experimental OT, data from 12 stenosis channels using a single sample of human blood were used to calculate the mean and SD.

Increasing soluble VWF concentration enhances SIPA rate and shortens time to occlusion. Agglomeration (A) and superficial velocity (C) over time for VWF concentrations ranging from 0.1 times to 18 times normal. Higher VWF concentrations cause faster agglomeration and decrease the traveling velocity. The corresponding agglomeration rate (B) and capture time (D) calculated based on (A) and (C), respectively. (E) Increasing the concentration of soluble VWF by 20-fold leads to 50% reduction of the OT. The API was inverted as 400-API. (F) The predicted enhancement of SIPA rates (in terms of agglomeration rate and 1/capture time) are elevated for high sVWF concentration that leads to an enhanced rate for arterial occlusion plotted as 1/OT from experiments. (***P < .0001). For each experimental OT, data from 12 stenosis channels using a single sample of human blood were used to calculate the mean and SD.

Close Modal

or Create an Account

Close Modal
Close Modal